

Ref. No.: NLL/CS/2024-427

November 14, 2024

To

1. National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051
Symbol: NECLIFE

2. BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001
Scrip Code: 532649

Sub: Outcome of Board Meeting

Ref.: Regulation 30 and 33 of Securities and Exchange Board of India (“SEBI”) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR Regulation”).

Dear Sir/ Madam,

We wish to inform you that the Board of Directors in their meeting held on November 14, 2024, have inter-alia noted decided and approved the following matters:

1. the limited reviewed Unaudited Standalone and Consolidated Financial results, Statements of Assets & Liabilities and Cash Flow Statements for the quarter and half year ended on September 30, 2023, which are enclosed herewith along with the Limited Review Reports of the Auditors thereon;
2. amended the Materiality of Information Policy as per provisions of extant LODR Regulations. The amended policy has been updated on the website of the Company at <https://www.necLife.com/about-3-5>.

As per policy and pursuant to regulation 30(5) of LODR Regulations, please note that:

The details of Key Managerial Personnel (“KMP”) authorized for the purpose of determining materiality of an event/information.

The Chief Executive Officer (“CEO”) or in his absence, Chairman & Managing Director (“CMD”) of the Company:

Name	Designation	E-mail	Address and Phone No.
Amit Chadah	CEO	bd@necLife.com	Nectar Lifesciences Limited SCO 38-39, Sector 9-D, Chandigarh – 160009. Tel.: +91-172-5047916

For the purpose of making disclosure to the Stock Exchanges as approved by the Board of Directors of the Company:

The Compliance Officer (“CO”) or in his/ her absence, the Company Secretary (if other than CO) or Chief Financial Officer (“CFO”) of the Company:

Name	Designation	E-mail	Address and Phone No.
Neha Vaishnav	CO	cs@neclife.com	Nectar Lifesciences Limited SCO 38-39, Sector 9-D, Chandigarh – 160009. Tel.: +91-172-5047916

Further pursuant to amended policy, the functional head of units no. 6 and 7, Baddi, Himachal Pradesh shall be deemed to be CEO of the Company. Therefore, the heads of units no. 6 and 7, Baddi, Himachal Pradesh shall be ceased to be a part of senior management with immediate effect.

The Board meeting commenced at 11.30 A.M. and concluded at 1:25 P.M.

Kindly take the same on record.

Thanking you,
Yours faithfully,
For **Nectar Lifesciences Limited**


(Neha Vaishnav)
Company Secretary & Compliance Officer



Independent Auditor's review report on the Quarterly and Half Yearly Unaudited Standalone Financial Results of the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of,
Nectar Lifesciences Limited,
Village Saidpura, Tehsil Derabassi,
Distt. S.A.S. Nagar (Mohali) Punjab

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Nectar Lifesciences Limited ("the Company") for the quarter and half year ended Sept 30, 2024 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review




is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Deepak Jindal & Co.
Chartered Accountants

Firm-Regn. No. 023023N



Date: 14th Nov 2024

Place: Chandigarh

M. No. 514746

UDIN: 24514746BKAE DU3496



Independent Auditors' review report on the Quarterly and half yearly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended

To
The Board of Directors
Nectar Lifesciences Limited
Village Saidpura, Tehsil Derabassi,
Distt. S.A.S. Nagar (Mohali) Punjab

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Nectar Lifesciences Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter and half year ended Sept 30, 2024 ("the Statement"), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been compiled from the related consolidated financial statements and been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial & accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the subsidiaries listed as below: -
 - a. NECLIFE PT, UNIPESSOAL LDA (Inoperative)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, including the matter in which it is to be disclosed, or that it contains any material misstatement.
6. The unaudited consolidated financial results include the unaudited interim financial information of the subsidiary which have not been reviewed by their auditors, whose interim financial information excluding consolidation eliminations reflects total revenue of Nil, total net profit/ (loss) after tax of Nil, total comprehensive income of Nil for the quarter ended Sept 30, 2024 and half year ended Sept 30, 2024, respectively, as considered in the Statement. The unaudited financial information has been approved and furnished to us by the management. Our conclusion in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited financial information. According to the information and explanations given to us by management, this interim financial information's are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the management.

For Deepak Jindal & Co.
Chartered Accountants
Firm Regn. No. 023023N



Date: 14th Nov 2024
Place: Chandigarh

M. No. 514746
UDIN:24514746BKAEDV8700

NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali), Punjab - 140507, Tel. +91-17 62-534 001, Email : cs@neclife.com, Website : www.neclife.com,
[CIN: L24232PB1995PLC016664]


Statement of Standalone Financial Results for the Quarter and half year ended 30.09.2024 (Rs in Lacs)

S. No.	Particulars	Quarter Ended			Half Year		Year Ended
		30-Sep-24	30-Jun-24	30-Sep-23	30-Sep-24	30-Sep-23	31-Mar-24
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Income from Operations						
	Sales	49,744.73	41,750.91	44,962.85	91,495.64	90,063.12	1,92,583.19
	Less: GST Recovered	6,956.27	5,866.21	5,167.14	12,822.48	10,855.78	24,174.62
	Revenue from Operations	42,788.46	35,884.70	39,795.71	78,673.16	79,207.34	1,68,408.57
	Other operating Income	21.33	45.27	0.62	66.60	1.25	154.56
II	Other Income	68.94	55.08	1,060.83	124.02	1,108.14	1,303.00
III	Total Income (I + II)	42,878.73	35,985.05	40,857.16	78,863.78	80,316.73	1,69,866.13
IV	Expenses						
	(a) Cost of Materials consumed	25,388.87	29,698.35	25,615.94	55,087.22	53,981.21	1,24,244.99
	(b) Purchase of Stock in Trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	4,215.53	(5,964.12)	3,162.78	(1,748.59)	2,714.26	(4,020.82)
	(d) Employee benefits expense	2,417.97	2,398.66	2,030.93	4,816.63	3,910.55	8,467.08
	(e) Finance costs	1,980.79	1,997.68	2,051.92	3,978.47	3,814.17	8,714.17
	(f) Depreciation and amortisation expense	1,554.87	1,546.03	1,531.23	3,100.90	3,064.48	6,071.84
	(g) Other expenses	6,454.09	5,816.74	6,300.21	12,270.83	12,362.07	24,561.27
	Total Expenses (IV)	42,012.12	35,493.34	40,693.01	77,505.46	79,846.74	1,68,038.53
V	Profit before exceptional items and tax (III- IV)	866.61	491.71	164.15	1,358.32	469.99	1,827.60
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit from ordinary activities before tax (V - VI)	866.61	491.71	164.15	1,358.32	469.99	1,827.60
VIII	Tax Expense						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	306.72	194.80	62.62	501.52	186.42	1,327.43
IX	Profit for the period from continuing operations (VII-VIII)	559.89	296.91	101.53	856.80	283.57	500.17
	Other Comprehensive Income						
	Items that will not be reclassified subsequently to profit or loss						
	Remeasurement of the net defined benefit liability/asset (Net of Tax)	-	-	-	-	-	(34.19)
	Items that will be reclassified subsequently to profit or loss						
	Foreign Exchange Translation Reserve (Net of Tax)	-	-	-	-	-	-
	Total Other Comprehensive Income, (Net of Tax)						(34.19)
	Total Comprehensive Income for the period	559.89	296.91	101.53	856.80	283.57	465.98
X	Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up)						
	a) Basic (In Rs.) - After Exceptional Item	0.25	0.13	0.05	0.38	0.13	0.22
	b) Basic (In Rs.) - Before Exceptional Item	0.25	0.13	0.05	0.38	0.13	0.22
	c) Diluted (In Rs.) - After Exceptional Item	0.25	0.13	0.05	0.38	0.13	0.22
	d) Diluted (In Rs.) - Before Exceptional Item	0.25	0.13	0.05	0.38	0.13	0.22



Statement of Consolidated Financial Results for the Quarter and half year ended 30.09.2024 (Rs in Lacs)

S. No.	Particulars	Quarter Ended			Half Year		Year Ended
		30-Sep-24	30-Jun-24	30-Sep-23	30-Sep-24	30-Sep-23	31-Mar-24
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Income from Operations						
	Sales	49,744.73	41,750.91	44,962.85	91,495.64	90,063.12	1,92,583.19
	Less: GST Recovered	6,956.27	5,866.21	5,167.14	12,822.48	10,855.78	24,174.62
	Revenue from Operations	42,788.46	35,884.70	39,795.71	78,673.16	79,207.34	1,68,408.57
	Other operating Income	21.33	45.27	0.62	66.60	1.25	154.56
II	Other Income	68.94	55.08	1,060.83	124.02	1,108.14	1,303.00
III	Total Income (I + II)	42,878.73	35,985.05	40,857.16	78,863.78	80,316.73	1,69,866.13
IV	Expenses						
	(a) Cost of Materials consumed	25,388.87	29,698.35	25,615.94	55,087.22	53,981.21	1,24,244.99
	(b) Purchase of Stock in Trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	4,215.53	(5,964.12)	3,162.78	(1,748.59)	2,714.26	(4,020.82)
	(d) Employee benefits expense	2,417.97	2,398.66	2,030.93	4,816.63	3,910.55	8,467.08
	(e) Finance costs	1,980.79	1,997.68	2,051.92	3,978.47	3,814.17	8,714.17
	(f) Depreciation and amortisation expense	1,554.87	1,546.03	1,531.23	3,100.90	3,064.48	6,071.84
	(g) Other expenses	6,454.09	5,816.74	6,300.21	12,270.83	12,362.07	24,561.98
	Total Expenses (IV)	42,012.12	35,493.34	40,693.01	77,505.46	79,846.74	1,68,039.24
V	Profit before exceptional items and tax (III- IV)	866.61	491.71	164.15	1,358.32	469.99	1,826.89
VI	Exceptional Items						
VII	Profit from ordinary activities before tax (V - VI)	866.61	491.71	164.15	1,358.32	469.99	1,826.89
VIII	Tax Expense						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	306.72	194.80	62.62	501.52	186.42	1,327.43
IX	Profit for the period from continuing operations (VII-VIII)	559.89	296.91	101.53	856.80	283.57	499.46
	Other Comprehensive Income						
	Items that will not be reclassified subsequently to profit or loss						
	Remeasurement of the net defined benefit liability/asset (Net of Tax)	-	-	-	-	-	(34.19)
	Items that will be reclassified subsequently to profit or loss						
	Foreign Exchange Translation Reserve (Net of Tax)	-	-	-	-	-	0.06
	Total Other Comprehensive Income, (Net of Tax)						(34.13)
	Total Comprehensive Income for the period	559.89	296.91	101.53	856.80	283.57	465.33
X	Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up)						
	a) Basic (In Rs.) - After Exceptional Item	0.25	0.13	0.05	0.38	0.13	0.22
	b) Basic (In Rs.) - Before Exceptional Item	0.25	0.13	0.05	0.38	0.13	0.22
	c) Diluted (In Rs.) - After Exceptional Item	0.25	0.13	0.05	0.38	0.13	0.22
	d) Diluted (In Rs.) - Before Exceptional Item	0.25	0.13	0.05	0.38	0.13	0.22



Notes

- 1 The above financial results were reviewed by Audit Committee on November 14, 2024 and approved by the Board in its meeting held on November 14, 2024. The statutory auditors of the Company have conducted a "Limited Review" of the above standalone and consolidated unaudited financial results/ statements for the quarter and half year ended on September 30, 2024.
- 2 The company is exclusively in the pharmaceutical business segment.
- 3 Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- 4 The Statement of Assets and Liability is attached as Annexure 1.
- 5 The Statement of Cash Flow is attached as Annexure 2.




**By Order of the Board of Directors
of Nectar Lifesciences Limited**

A handwritten signature in blue ink, appearing to read "Sanjiv Goyal", written over a faint horizontal line.

**Dated: 14.11.2024
Place: Chandigarh**

**(Sanjiv Goyal)
Chairman & Managing Director**



Statement of Assets and Liabilities

(Rs. in Lakhs)

Sr.	Particulars	Standalone as at		Consolidated as at	
		30-Sep-24	31-Mar-24	30-Sep-24	31-Mar-24
		Unaudited	Audited	Unaudited	Audited
	Assets				
1	Non-current assets				
	Property, plant and equipment	57,639.04	59,031.18	57,639.04	59,031.18
	Capital work-in-progress	5,690.19	6,574.96	5,690.19	6,574.96
	Investment property	-	-	-	-
	Goodwill	-	-	-	-
	Other intangible assets	5,074.05	5,239.28	5,074.05	5,239.28
	Intangible assets under development	-	-	-	-
	Biological assets other than bearer plants	-	-	-	-
	Inventories	17,733.10	17,794.17	17,733.10	17,794.17
	Investments accounted for using equity method	-	-	-	-
	Non-current investments	24.31	24.31	23.51	23.51
	Trade receivables, non-current	815.41	815.41	815.41	815.41
	Loans, non-current	-	-	-	-
	Other non-current financial assets	341.11	284.27	341.11	284.27
	Deferred tax assets (net)	246.30	747.83	246.25	747.78
	Other non-current assets	217.35	211.78	217.35	211.78
	Total non-current assets	87,780.86	90,723.19	87,780.01	90,722.34
2	Current assets				
	Inventories	74,938.11	70,915.15	74,938.11	70,915.15
	Current investments	49.48	49.48	49.48	49.48
	Trade receivables, current	37,927.01	37,919.35	37,927.01	37,919.35
	Cash and cash equivalents	1,823.83	1,980.42	1,824.01	1,980.60
	Bank balance other than cash and cash equivalents	-	-	-	-
	Loans, current	86.41	92.36	86.41	92.36
	Other current financial assets	750.59	922.04	750.59	922.04
	Current tax assets (net)	-	-	-	-
	Other current assets	14,967.73	16,504.31	14,967.73	16,504.31
	Total current assets	1,30,543.16	1,28,383.11	1,30,543.34	1,28,383.29
3	Non-current assets classified as held for sale	-	-	-	-
4	Regulatory deferral account debit balances and related deferred tax Assets	-	-	-	-
	Total assets	2,18,324.02	2,19,106.30	2,18,323.35	2,19,105.63
	Equity and liabilities				
1	Equity				
	Equity attributable to owners of parent				
	Equity share capital	2,242.61	2,242.61	2,242.61	2,242.61
	Other equity	1,05,539.65	1,04,682.84	1,05,538.98	1,04,682.17
	Total equity attributable to owners of parent	1,07,782.26	1,06,925.45	1,07,781.59	1,06,924.78
	Non controlling interest	-	-	-	-
	Total equity	1,07,782.26	1,06,925.45	1,07,781.59	1,06,924.78
2	Liabilities				
	Non-current liabilities				
	Non-current financial liabilities				
	Borrowings, non-current	9,946.98	14,030.87	9,946.98	14,030.87
	Lease liabilities	-	-	-	-
	Trade payables, non-current	-	-	-	-
	(A) total outstanding dues of micro enterprises and small enterprises;	-	-	-	-
	(B) total outstanding dues of creditors other than micro enterprises and small enterprises	-	-	-	-
	Other non-current financial liabilities	-	-	-	-
	Provisions, non-current	793.69	793.69	793.69	793.69
	Deferred tax liabilities (net)	-	-	-	-
	Deferred government grants, Non-current	-	-	-	-
	Other non-current liabilities	73.33	74.58	73.33	74.58
	Total non-current liabilities	10,814.00	14,899.14	10,814.00	14,899.14
	Current liabilities				
	Current financial liabilities				
	Borrowings, current	52,964.61	49,522.76	52,964.61	49,522.76
	Lease liabilities	-	-	-	-
	Trade payables, current	-	-	-	-
	(A) total outstanding dues of micro enterprises and small enterprises;	994.11	1,086.18	994.11	1,086.18
	(B) total outstanding dues of creditors other than micro enterprises and small enterprises	40,306.27	40,879.94	40,306.27	40,879.94
	Other current financial liabilities	2,932.61	3,873.04	2,932.61	3,873.04
	Other current liabilities	2,211.32	1,697.65	2,211.32	1,697.65
	Provisions, current	318.84	222.14	318.84	222.14
	Current tax liabilities (Net)	-	-	-	-
	Deferred government grants, current	-	-	-	-
	Total current liabilities	99,727.76	97,281.71	99,727.76	97,281.71
3	Liabilities directly associated with the disposal of group classified as held for sale	-	-	-	-
4	Regulatory deferral account debit balances and related deferred tax liability	-	-	-	-
	Total liabilities	1,10,541.76	1,12,180.85	1,10,541.76	1,12,180.85
	Total equity and liabilities	2,18,324.02	2,19,106.30	2,18,323.35	2,19,105.63

Unaudited Cash Flow Statement

(Rs. In Lakhs)

PARTICULARS	Standalone		Consolidated	
	Half year ended		Half year ended	
	30-Sep-24	30-Sep-23	30-Sep-24	30-Sep-23
<u>CASH FLOW FROM OPERATING ACTIVITIES</u>				
Net profit before Tax & Extra Ordinary Items	1,358.32	469.98	1,358.32	469.98
Adjustments For :	-	-	-	-
Depreciation & Amortization	3,100.90	3,064.48	3,100.90	3,064.48
Other Comprehensive Income (Net)	-	-	-	-
Other Comprehensive Income (Tax)	-	-	-	-
Provision for Doubtful debts/ Insurance Claims	170.81	-	170.81	-
Provision for Employees Retirement Benefits	96.70	34.31	96.70	34.31
Provision for Excise Duty On Finished Goods	-	-	-	-
Loss/ (Profit) on Sale of Fixed Assets	-	-	-	-
Interest on Borrowings	3,978.47	3,814.17	3,978.47	3,814.17
Other Non-Operating Income	(124.02)	(1,108.14)	(124.02)	(1,108.14)
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	8,581.18	6,274.80	8,581.18	6,274.80
Adjustments For :				
(Increase)/Decrease in Current Assets	(2,487.44)	2,549.77	(2,487.44)	2,549.77
Increase/(Decrease) in Current Liabilities	(1,092.50)	2,290.77	(1,092.50)	2,290.77
Increase/(Decrease) in Long Term Liabilities	-	-	-	-
Increase/ (Decrease) in Non Current Liabilities	(1.25)	(1.25)	(1.25)	(1.25)
(Increase)/ Decrease in Non Current Assets	(1.34)	477.98	(1.34)	477.98
CASH GENERATED FROM OPERATIONS	4,998.65	11,592.07	4,998.65	11,592.07
Direct Taxes Paid	-	-	-	-
CASH FLOW BEFORE EXTRA-ORDINARY ITEMS	4,998.65	11,592.07	4,998.65	11,592.07
Extra-Ordinary Items	-	-	-	-
NET CASH FLOW FROM OPERATING ACTIVITIES (A)	4,998.65	11,592.07	4,998.65	11,592.07
<u>CASH FLOW FROM INVESTING ACTIVITIES</u>				
Purchase of Fixed Assets	(658.75)	(1,384.59)	(658.75)	(1,384.59)
Interest Received	100.05	1,108.14	100.05	1,108.14
Dividend Received	-	-	-	-
Maturity of insurance policies	23.97	-	23.97	-
Other Financial Assets Received/ (Paid)	-	-	-	-
NET CASH USED IN INVESTING ACTIVITIES (B)	(534.73)	(276.45)	(534.73)	(276.45)
<u>CASH FLOW FROM FINANCING ACTIVITIES</u>				
Proceeds/(Repayment) from Term Loans from Banks	(4,180.97)	(3,513.44)	(4,180.97)	(3,513.44)
Proceeds/(Repayment) from Working Capital Limits from Banks	3,552.81	(3,734.23)	3,552.81	(3,734.23)
Proceeds/(Repayment) from Vehicle Loans	(13.88)	(8.16)	(13.88)	(8.16)
Dividend Paid	-	-	-	-
Interest Paid	(3,978.47)	(3,814.17)	(3,978.47)	(3,814.17)
NET CASH GENERATED FROM FINANCING ACTIVITIES (C)	(4,620.51)	(11,070.00)	(4,620.51)	(11,070.00)
NET INCREASE/(DECREASE) IN CASH & CASH EQUIVALENTS (A+B+C)	(156.59)	245.62	(156.59)	245.62
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	1,980.42	1,757.20	1,980.60	1,758.00
CASH & CASH EQUIVALENTS AT THE CLOSE OF THE YEAR	1,823.83	2,002.82	1,824.01	2,003.62

